Biologic Therapies, Psoriasis, and COVID-19: Our Experience at the Psoriasis Unit of the University of Naples Federico II.

Camela, Elisa; Fabbrocini, Gabriella; Cinelli, Eleonora; Lauro, Wanda; Megna, Matteo

Camela, Elisa; Fabbrocini, Gabriella; Cinelli, Eleonora; Lauro, Wanda; Megna, Matteo.

Camela E; Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
Fabbrocini G; Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
Cinelli E; Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
Lauro W; Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
Megna M; Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy, mat24@libero.it.

Dermatology ; 237(1): 13-14, 2021.

Article in English | MEDLINE | ID: covidwho-965835

Subject(s)

Biological Products/therapeutic use; COVID-19/epidemiology; Psoriasis/drug therapy; Adalimumab/therapeutic use; Adult; Aged; Dermatologic Agents/therapeutic use; Etanercept/therapeutic use; Female; Humans; Italy/epidemiology; Male; Middle Aged; Risk Factors; SARS-CoV-2

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Psoriasis / Biological Products / COVID-19 Type of study: Observational study / Prognostic study Limits: Adult / Aged / Female / Humans / Male / Middle aged Country/Region as subject: Europa Language: English Journal: Dermatology Journal subject: Dermatology Year: 2021 Document Type: Article Affiliation country: 000513575

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google